Archive for May, 2012

27-05-2012 05:31 05/25/2012 Women have many options when it comes to birth control, while men don't have any. But all that could change. Researchers have discovered a gene that is essential to the production of sperm. Scientists at the University of Edinburgh found that the gene, called Katnal1, causes temporary infertility in male mice when blocked. The team gave mice a chemical called ENU that triggers genetic mutations. They then bred the mice to see if any of them became infertile, isolated the impotent mice, and backtracked through their genetic code to identify which gene was disrupted by ENU. The team identified that Katnal1 is used to regulate a structure known as microtubules, which are the parts of sperm needed for nutrients and support. According to the study, this gene could be key in developing birth control for men, and better understanding male infertility. With this key bit of information, scientists say a non-hormonal contraceptive for men may be just five to 10 years away. This video is [FAIR USE], under © COPYRIGHT LAW it is: ? noncommercial ? trans-formative in nature ? not competitive with the original work ? not effecting its market negatively ? Thank you. [FAIR USE NOTICE]: [This video contains copyrighted material the use of which has not always been specifically authorized by the copyrig owner. We are making such material available in our efforts to advance understandichtice issues, etc. We believe this constitutes a 'fair use' of any such ...

Continued here:
New Sperm Gene Discovery Could Lead to Male BIRTH CONTROL [©IBTimesTV] - Video

Editor's Choice Main Category: Cancer / Oncology Also Included In: Genetics Article Date: 28 May 2012 - 16:00 PDT

Current ratings for: 'Chronic Inflammation Gene May Destroy Tumors'

Robert J. Schneider, PhD, the Albert Sabin Professor of Molecular Pathogenesis and associate director for translational research and co-director of the Breast Cancer Program at the NYU Langone Medical Center, who was the principal investigator of the study, declared:

Scientists have known for decades that accelerated ageing, inflammation and cancer are somehow related, yet exactly how these conditions are linked has so far been unknown. The little knowledge available has partly been obtained in Schneider's previous studies, mainly that a gene called AUF1 controls inflammation by switching off the inflammatory response to prevent the onset of septic shock, and although this finding is significant, it fails to shed light on the link to ageing and cancer. The team observed that accelerated ageing occurred when the AUF1 gene was deleted, which led them to investigate further. A decade later, they have finally discovered the link between inflammation, advanced aging and cancer.

They found out that aside from controlling inflammation, AUF1, which belongs to a family of four related genes, also maintains the integrity of chromosomes. It activates telomerase, an enzyme, to repair the ends of chromosomes, and by doing so, it simultaneously reduces inflammation, prevents rapid aging and cancer from developing. Dr. Schneider explained: "AUF1 is a medical and scientific trinity. Nature has designed a way to simultaneously turn off harmful inflammation and repair our chromosomes, thereby suppressing aging at the cellular level and in the whole animal."

Armed with this new discovery, Dr. Schneider and his team are currently researching how the alterations manifest and present themselves clinically. They are examining human populations for specific types of genetic changes in the AUF1 gene, which are associated with rapid ageing, higher risk of cancer and co-developments of certain immune diseases.

Written By Petra Rattue Copyright: Medical News Today Not to be reproduced without permission of Medical News Today

MLA

Petra Rattue. "Chronic Inflammation Gene May Destroy Tumors." Medical News Today. MediLexicon, Intl., 28 May. 2012. Web. 29 May. 2012. <http://www.medicalnewstoday.com/articles/245916.php>

Please note: If no author information is provided, the source is cited instead.

Continued here:
Chronic Inflammation Gene May Destroy Tumors

Obituaries

May 28, 2012

Dr. David Rimoin

Dr. David Rimoin, a pioneering physician and researcher in the field of medical genetics, died May 27, 2012 at the age of 76.

Dr. Rimoin succumbed after a private battle with pancreatic cancer.

Colleagues and friends, many of whom were not aware of his sudden diagnosis, reacted with shock.

We have lost a giant in the field of medicine, said an official statement from the Cedars Sinai board of directors. His medical contributions will continue to bring healing for generations.

Dr. Rimoin held the Steven Spielberg Family Chair in Pediatrics and was Director of the Medical Genetics Institute at Cedars Sinai Medical Center. He was also Professor of Pediatrics, Medicine and Human Genetics at the David Geffen School of Medicine at UCLA. At Cedars, he conducted groundbreaking research into dwarfism and skeletal dysplasia. His 1970 demonstration that diabetes mellitus was the reflection of multiple genetic variants laid the foundation for the field of common disease genetics. His 1983 textbook, Emery and Rimoins Principles and Practice of Medical Genetics remains a classic in the field. Dr. Rimoin published over 400 articles in peer-reviewed journals.

David Rimoin was born in 1936 in Montreal, Canada. He earned his PhD from McGill Medical School in 1961, and received his PhD in human genetics in 1967 from Johns Hopkins.

In 1970 he arrived in LA, where he built the division of human genetics first at Harbor-UCLA Medical Center, then at Cedars Sinai.

Read more:
Dr. David Rimoin, pioneering geneticist, dies at 76

FARMINGTON

Dr. Frank Torti, the University of Connecticut Health Center's new vice president of health affairs, says that personalized medicine could be the next big thing in health care and that he expects the university to play a major role in it.

With UConn's work in genomics and the upcoming arrival of genetic research company Jackson Laboratory to campus, Torti said the health center is well-positioned to advance the field of personalized medicine, in which a patient's genetic information is used to customize treatment for a particular condition.

"Where we want UConn to lead is where we can actually begin to identify for individual patients drugs that are likely to work for them and be able to identify drugs that are likely to produce toxicity," Torti said, sitting in his new, sparsely furnished office. "If we can do that, we would change the face of how medicine is delivered. If we can do that, people will laugh at 20th-century and early 21st-century medicine the way that we now laugh at some of the things that were done in the 19th century, because we will have changed the way that we conceptualize how to treat a patient for a disease."

Now four weeks into his new position, Torti recently outlined his goals for the next few years.

"We want to find those areas, those intersections where science is going nationally and worldwide that's one part of the question," he said. "The other part of it is where does UConn currently, or could, have a unique contribution to that?"

Developing science is only half the battle. Actually getting it to the public is the other half. Negotiating the maze of the drug approval process is a matter that requires its own expertise, he said, and his earlier work as chief scientist and acting commissioner of the U.S. Food and Drug Administration should help significantly in that respect.

"I have seen many good compounds, many good potential drugs never reach patients not because they weren't effective, but because the [developer] did not understand the pathway to get that drug approved," he said. "This is a science in its own right. This is a science that I bring to UConn."

UConn President Susan Herbst said that Torti's FDA experience was one reason she wanted to bring him to the health center.

"Drug discovery is a critical part of what we're going for," she said. "With our investment in genomics and in stem cell research, we need the expertise of someone who understands the drug approval process. To have someone who led the FDA, that's special and unusual for a university."

Go here to see the original:
New UConn Health Center Chief Looks Ahead

28 May 2012 Last updated at 09:14 ET

A 54m cutting-edge stem cell research centre in Edinburgh has been officially opened by the Princess Royal.

The Royal opened the Scottish Centre for Regenerative Medicine as well as the 24m bio-incubator facility, Nine, in the Edinburgh BioQuarter.

Research into conditions such as multiple sclerosis and heart and liver disease will benefit from the new facilities in Little France.

The Princess Royal unveiled plaques at the centres.

Edinburgh University's Scottish Centre for Regenerative Medicine is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists.

The centre, funded by Edinburgh University, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, is being opened by the Princess Royal in her role as Chancellor of Edinburgh University.

It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies.

Nine, which has been jointly funded by Scottish Enterprise and the UK government's department for business, innovation and skills, has 85,000 sq ft of laboratory and office space for both established biotechnology companies and start-up ventures.

The Edinburgh BioQuarter is in the city's Little France area and includes the Royal Infirmary of Edinburgh and Edinburgh University's Queen's Medical Research Institute and Chancellor's Building.

Here is the original post:
Princess opens stem cell centre

THE MAKATI Medical Centers Cancer Center celebrated its first year anniversary and marked the occasion with the launch of its Cellular Therapeutics Laboratory. Present at the ribbon-cutting ceremony were Dr. Eric Flores, head, Spine Clinic and Stem Cell Lab; Rosalie Montenegro, Makati Medical Center president and CEO; Dr. ManuelO. Fernandez Jr., executive vice president and director, Professional Services; Dr. Remedios G. Suntay, director and treasurer, MDI Board; Dr. Benjamin N. Alimurung, medical director; Dr. Francis Chung, scientific officer, Stem Cell Lab; and Augusto P. Palisoc Jr., executive director, president and CEO, MPIC Hospital Group.

MAKATIMEDS Cellular Therapeutics Laboratory is managed by experienced scientists with extensive training and is affiliated with the International Society for Cellular Therapy.

Stem cell therapy is now being offered at Makati Medical Center (MMC) as potential cure for a wide range of illnesses, from various types of cancer and heart ailments to incurable diseases such as multiple sclerosis, Parkinsons and Alzheimers.

Stem cell therapy is believed to be effective in bone marrow transplant for leukemia patients, and with early intervention, yields desirable results among renal and prostate cancer patients.

Launched in the first year anniversary of the hospitals cancer center, MMCs Cellular Therapeutics Laboratory is equipped with technology touted to be totally unmatched in our country, says Dr. Francis Chung, scientific officer of the lab. No system exists elsewhere.

Employing the strictest sterility standards at par with that of the US Food and Drug Administration, the lab has state-of-the-art facilities. The Clinimacs CD34 Reagent System is a machine that isolates specific cells needed for the procedure, while the Flow Cytomer ensures the purity of cultured cells.

Transplantation

Sourcing the stem cells, however, is what truly sets the Philippines premier health institution apart from chi-chi spas that also push stem cell therapy for beauty and anti-aging procedures.

At MMC, healthy stem cells are acquired from the patients themselves, a process known as autologous transplantation. For those suffering from an ailment, a parent, sibling or other close relative could be the donor. The hospital strives for utmost compatibility between patient and donor through a 10-point DNA matching system.

If a battery of tests finds a patient to be up to it, medication is given to prepare him for stem cell harvest.

See the original post:
Makati Medical Center now offering stem cell therapy

Hip replacements for some patients could be a thing of the past after surgeons pioneered a new stem cell procedure to tackle a bone disease that leads to arthritis.

Doctors at Southampton General Hospital are extracting stem cells from the bone marrow of patients in need of hip repair due to osteonecrosis - a condition where poor blood supply causes significant bone damage leading to severe arthritis.

These cells are mixed with cleaned, crushed bone from another patient who has had their own hip replaced and used to fill the hole made by surgeons after dead and damaged tissue has been removed from the joint.

The procedure has been developed by Doug Dunlop, a consultant orthopaedic surgeon at Southampton General Hospital, and Professor Richard Oreffo, a specialist in musculoskeletal science at the University of Southampton.

"Although this work is still ongoing, several patients who have had the procedure have reacted very well and, if we get the results we are hoping for, these patients won't need to have their hip joints replaced - they should be fixed completely," said Mr Dunlop.

Professor Oreffo added: "By using stem cells to send out chemical signals to blood vessels, we hope the body will continue to create new vessels in the hip which supply enough nutrients to maintain bone strength."

Osteonecrosis is on the rise in the UK with around 4,000 cases a year but it is much more widespread in Asia where it is the most common form of arthritis of the hip, the hospital said.

It can also be treated with drugs to help avoid arthritis and usually strikes between 30 and 50 years of age.

Osteonecrosis is one of the three main causes of arthritis alongside osteoarthritis and rheumatoid arthritis.

Arthritis in general affects one in five people in the UK.

Read the rest here:
Stem cell hope for hip replacement procedure

THE MAKATI Medical Centers Cancer Center celebrated its first year anniversary and marked the occasion with the launch of its Cellular Therapeutics Laboratory. Present at the ribbon-cutting ceremony were Dr. Eric Flores, head, Spine Clinic and Stem Cell Lab; Rosalie Montenegro, Makati Medical Center president and CEO; Dr. ManuelO. Fernandez Jr., executive vice president and director, Professional Services; Dr. Remedios G. Suntay, director and treasurer, MDI Board; Dr. Benjamin N. Alimurung, medical director; Dr. Francis Chung, scientific officer, Stem Cell Lab; and Augusto P. Palisoc Jr., executive director, president and CEO, MPIC Hospital Group.

MAKATIMEDS Cellular Therapeutics Laboratory is managed by experienced scientists with extensive training and is affiliated with the International Society for Cellular Therapy.

Stem cell therapy is now being offered at Makati Medical Center (MMC) as potential cure for a wide range of illnesses, from various types of cancer and heart ailments to incurable diseases such as multiple sclerosis, Parkinsons and Alzheimers.

Stem cell therapy is believed to be effective in bone marrow transplant for leukemia patients, and with early intervention, yields desirable results among renal and prostate cancer patients.

Launched in the first year anniversary of the hospitals cancer center, MMCs Cellular Therapeutics Laboratory is equipped with technology touted to be totally unmatched in our country, says Dr. Francis Chung, scientific officer of the lab. No system exists elsewhere.

Employing the strictest sterility standards at par with that of the US Food and Drug Administration, the lab has state-of-the-art facilities. The Clinimacs CD34 Reagent System is a machine that isolates specific cells needed for the procedure, while the Flow Cytomer ensures the purity of cultured cells.

Transplantation

Sourcing the stem cells, however, is what truly sets the Philippines premier health institution apart from chi-chi spas that also push stem cell therapy for beauty and anti-aging procedures.

At MMC, healthy stem cells are acquired from the patients themselves, a process known as autologous transplantation. For those suffering from an ailment, a parent, sibling or other close relative could be the donor. The hospital strives for utmost compatibility between patient and donor through a 10-point DNA matching system.

If a battery of tests finds a patient to be up to it, medication is given to prepare him for stem cell harvest.

Link:
Makati Medical Center now offering stem cell therapy

Sarada Krishnan, director of horticulture at the Denver Botanic Gardens, holds coffee tree leaves she collected recently from a trip to South Sudan to study the DNA of the plants. (Cyrus McCrimmon, The Denver Post)

Coffee didn't alter the direction of Sarada Krishnan's life. It merely flowed through it.

She was a year into her Ph.D. at the University of Colorado at Boulder, focusing on Prunus africana, an endangered tree in Madagascar. After a year of toil reviewing all the previous research, she found out the grant she'd been hoping would fund her project had been given to another scholar.

"I was devastated," she said. "After a year of working on it, I had to completely start over."

She opened a book, and a photograph fell out. It showed her late father, standing in the trees of her family's coffee plantation in the Wynad district of Kerala, an Indian state.

"I thought, 'Oh! Maybe I should work on coffee.' And it turned out there was a need for coffee research in Madagascar."

The liquid fuel that kick-starts so many mornings across the globe is anything but simple in horticulture, in commerce, in ethics. Coffee is the world's second-most widely traded commodity (oil is No. 1). It provides a living for 75 million people. The coffee fruit, whose "beans" are actually seeds, grows on trees in the subtropical mountains of Jamaica, Haiti, El Salvador, Ethiopia, Kenya 80 countries in all.

Preserving the genes of those coffee trees is what drives Krishnan, the Denver Botanic Gardens' horticulture director. And it drives her at 80 or 90 miles an hour. She talks fast, the words, big technical ones, tumbling out. Since powering through that bump on the way to her doctorate, she has bought two coffee plantations in Jamaica and is part-owner of a third; she'd like to use one of them for coffee research. She's consulted on efforts to revitalize the coffee industry in Haiti. She's waiting for her importer's license and certification to come through. She's divorced with two sons, Vinay, 19, and Vilok, 16.

Her favorite brew? Jamaican Blue Mountain,. Her drink at Starbucks? A triple-shot latte. "I do sugar and milk, which is sacrilege to real coffee experts. Sugar is bad enough, but milk! But that's how I grew up drinking it. And I started at 7 or 8 years old."

She drinks coffee. She farms coffee. She studies coffee. "For me, having the production side is beneficial to the scientific side and vice versa," she says.

Read this article:
Denver researcher works to study, preserve coffee beans' gene pool

Hip replacements for some patients could be a thing of the past after surgeons pioneered a new stem cell procedure to tackle a bone disease that leads to arthritis.

Doctors at Southampton General Hospital are extracting stem cells from the bone marrow of patients in need of hip repair due to osteonecrosis - a condition where poor blood supply causes significant bone damage leading to severe arthritis.

These cells are mixed with cleaned, crushed bone from another patient who has had their own hip replaced and used to fill the hole made by surgeons after dead and damaged tissue has been removed from the joint.

The procedure has been developed by Doug Dunlop, a consultant orthopaedic surgeon at Southampton General Hospital, and Professor Richard Oreffo, a specialist in musculoskeletal science at the University of Southampton.

"Although this work is still ongoing, several patients who have had the procedure have reacted very well and, if we get the results we are hoping for, these patients won't need to have their hip joints replaced - they should be fixed completely," said Mr Dunlop.

Professor Oreffo added: "By using stem cells to send out chemical signals to blood vessels, we hope the body will continue to create new vessels in the hip which supply enough nutrients to maintain bone strength."

Osteonecrosis is on the rise in the UK with around 4,000 cases a year but it is much more widespread in Asia where it is the most common form of arthritis of the hip, the hospital said.

It can also be treated with drugs to help avoid arthritis and usually strikes between 30 and 50 years of age.

Osteonecrosis is one of the three main causes of arthritis alongside osteoarthritis and rheumatoid arthritis.

Arthritis in general affects one in five people in the UK.

Read this article:
Stem cell hope for hip replacement procedure

28 May 2012 Last updated at 09:14 ET

A 54m cutting-edge stem cell research centre in Edinburgh has been officially opened by the Princess Royal.

The Royal opened the Scottish Centre for Regenerative Medicine as well as the 24m bio-incubator facility, Nine, in the Edinburgh BioQuarter.

Research into conditions such as multiple sclerosis and heart and liver disease will benefit from the new facilities in Little France.

The Princess Royal unveiled plaques at the centres.

Edinburgh University's Scottish Centre for Regenerative Medicine is the first large-scale, purpose-built facility of its kind and provides accommodation for up to 250 stem cell scientists.

The centre, funded by Edinburgh University, Scottish Enterprise, the Medical Research Council (MRC) and the British Heart Foundation through its Mending Broken Hearts Appeal, is being opened by the Princess Royal in her role as Chancellor of Edinburgh University.

It includes the most up-to-date facilities in the UK, which meet the highest guidelines, to manufacture stem cell lines that could be used for patient therapies.

Nine, which has been jointly funded by Scottish Enterprise and the UK government's department for business, innovation and skills, has 85,000 sq ft of laboratory and office space for both established biotechnology companies and start-up ventures.

The Edinburgh BioQuarter is in the city's Little France area and includes the Royal Infirmary of Edinburgh and Edinburgh University's Queen's Medical Research Institute and Chancellor's Building.

Continue reading here:
Princess opens stem cell centre

A TEAM of fundraisers was expecting to ride rickshaws into London today ending a mammoth challenge in aid of multiple sclerosis research.

Three rickshaws, six bikes and 14 people left the Clifton Suspension Bridge on Friday for the ride to London's Tower Bridge. The Bridge to Bridge Challenge expected to take four days and was due to finish today.

Cyclists gather on the Leigh Woods side of Clifton Suspension Bridge before setting off on their Bridge to Bridge Challenge to raise money for a Multiple Sclerosis research project at Frenchay Hospital Picture: Dan Regan BRDR20120525A001

Money raised will go towards a research project at Frenchay Hospital that is looking at using stem cells to repair the damage caused by multiple sclerosis (MS).

The challenge was the idea of Kieran Murphy whose partner Maria has MS. She was due to join him in the challenge but has had to go into hospital due to problems with her condition.

MS sufferers have been travelling in the back of the rickshaws for the challenge, including Bristol and Avon Multiple Sclerosis Centre voluntary fundraising manager Shaun McCarthy.

Speaking last night from Slough, Mr McCarthy said: "We are very tired and people have put a lot of effort in but it's going really well."

To sponsor the team visit http://www.justgiving.com/bramsrickshaw or text BRAM50 + DONATION to 70070.

View original post here:
The Post published No bridge too far for these charity riders

Burr, the drummer with Maiden from 1979 until 1982, has been in a wheelchair as a result of multiple sclerosis, which has been attacking his nervous system since before he was diagnosed in 2002.

MS reduces the ability of the brain and spinal cord to communicate with each other, resulting in a wide range of potentially severe symptoms. The cause is unknown and there is no cure; but in 2009 researchers made the first breakthrough in reversing symptoms through stem cell therapy.

Di'Anno tells Talking Metal Pirate Radio Burr's condition is "not very good at all." - He had a lot to say, read it here.

Classic Rock Magazine is an official news provider for antiMusic.com. Copyright Classic Rock Magazine- Excerpted here with permission.

antiMUSIC News featured on RockNews.info and Yahoo News

...end

Read the original post:
Di'Anno Wants Former Iron Maiden Bandmate To Undergo Stem Cell Therapy Recap

Public release date: 27-May-2012 [ | E-mail | Share ]

Contact: Craig Brierley c.brierley@wellcome.ac.uk 44-207-611-7329 Wellcome Trust

A gene previously linked to too much growth in patients has now also been linked to growth restriction. Different forms of the gene can lead to very different conditions, according to research published today in the journal Nature Genetics.

IMAGe* syndrome is a rare developmental disorder which can affect foetal growth, resulting in smaller than average body and organ size. Without treatment, the disorder can have potentially life-threatening consequences from adrenal gland failure.

The condition was first identified twenty years ago by Eric Vilain, then a researcher in France. Now, Professor Vilain and colleagues at the University of California, Los Angeles, together with researchers at the UCL Institute of Child Health in the UK, have identified the disorder as being caused by a particular mutation of a gene known as CDKN1C, found on chromosome 11. They made their discovery after analysing DNA samples from an Argentinian family affected by IMAGe syndrome, together with existing samples from patients collected over the past two decades.

Scientists have known for some time now that CDKN1C plays an important role in regulating cell growth. Mutations of this gene have been previously associated with an 'overgrowth' syndrome called Beckwith-Wiedemann syndrome, which causes large body parts and large organs and carries an increased risk of tumours. The link with IMAGe is the first time that the gene has been associated with growth restriction.

"We discovered a mutation in chromosome 11 that consistently appeared in every family member affected by IMAGe Syndrome," explains Professor Vilain. "We were a little surprised, though, because the mutation was located on a gene previously recognised as causing Beckwith-Wiedemann Syndrome. Finding dual functions in one molecule is an unusual biological phenomenon. These two diseases are polar opposites of each other.

"The results are particularly special for me as we have finally been able to identify the cause of the condition that I first encountered twenty years ago. This is a big step forward and should help affected families in the future. We can now use gene sequencing as a tool to screen for the mutation and diagnose children early enough for them to benefit from medical intervention."

In fact, the researchers found that IMAGe syndrome was only associated with changes in the maternal CDKN1C gene. If only the copy of the gene inherited from the father carried the mutation, the child was unaffected. This process of 'switching on' genes differently depending on whether they are inherited from the mother or the father is known as 'imprinting'. Some scientists believe that imprinted genes have evolved to play an important role in how the foetus develops in the womb; a smaller foetus carries an advantage to the mother as it increases her chances of survival during childbirth, whilst the father's genes may work to increase the birth size and hence chances of survival of the offspring.

Dr John Achermann, a Wellcome Trust Senior Research Fellow at the UCL Institute of Child Health, UCL, says: "Our surprising finding shows that different changes in the same gene can lead to very different effects. The results give us clues not only in relation to growth during human development, but also to how cells grow and divide and lead to tumours."

Read the original post:
Variations of a single gene can lead to too much or too little growth, study shows

27-05-2012 09:27 Special upload for webkinzgirle12 and turebeliever24 I DO NOT OWN THIS SHOW S05E14 Selective Breeding Lu treats a young patient with Bi-Polar disease which causes her to act hazardously violent. Her mother must decide whether to keep her or give her up to a mental institution. Meanwhile, Andy helps a woman have an invitro fertilization. She uses new technology to help the couple have a boy because of a genetic female-only disease in the family but later a web of lies and deceivements is revealed. Peter gets jealous when Kayla dates a man he volunteers for at a zoo.

Visit link:
Strong Medicine ''Selective Breeding'' 1/2 - Video

EURANGIE Park Murray Greys principal Malcolm Carson is pushing the boundaries of the breed through the outcross of genetics.

His cattle, be it Murray Grey, Angus, or a composite, are all Breedplan recorded and society registered in a quest to breed great cattle, no matter what the breed.

While Mr Carson believes the grey and silver cattle he breeds are more suited to the Australian climate than other breeds, he aims to uses good genetics in his herd, regardless of the colour.

"When it comes to breeding cattle, I am not locked into any one colour, and I have been using the best proven genetics for 11 years, be it Angus or Murray Grey," he said.

"A majority of my herd are recorded on the multi-breed register with the Angus and Murray Grey societies, as well as performance recorded with Breedplan.

"I would say they are Grey Angus cattle."

Mr Carson said people get "stuck in the tram tracks" and should look past the colour of an animal.

He is now running pure-bred Angus cows and pure-bred Murray Grey cows and uses artificial insemination to produce composites that are either 25 per cent, 50pc or 75pc Murray Grey.

Popular genetics are used in the herd to expand the gene pool, with Te Mania, Ardrossan and Lawson Angus bloodlines now present in the cattle.

Mr Carson is targeting high intramuscular fat, eye muscle area, 600-day growth rate and milking ability, as well as focusing strongly on temperament.

Link:
Eurangie Park's commitment to genetics

For Jonathan Provost, choosing his Eagle Scout project was an easy choice. Jonathan's cousin, Matthew Zieman, passed away from Acute Lymphatic Leukemia in February at the age of 24. Because of this, Jonathan's Eagle Scout project is a bone marrow donor registry drive.

"Matt was at his apartment last year and noticed a few bumps on the back of his neck," Jonathan said. "He just ignored them for a few weeks and then he told one of his friends, and she said to get it checked out. So he went by the hospital, they did a few tests, and they found out it was leukemia."

Jonathan hopes the drive will find a number of donors who can help current cancer patients, due to the difficulty of finding donor matches. Immediate family members are generally the first place doctors look for bone marrow donors; Matthew's only sibling wasn't a match, however, which made finding a donor more difficult.

The drive will be held from noon to 4 p.m. on Saturday, June 9, at Brad Duren Dentistry, located at 4030 Justin Road, Suite 102, in Flower Mound. The office is past the Chinn Chapel Soccer Complex and across from the Crossroads Bible Church. Jonathan chose the office partly because of its location and partly because of a familiarity.

"It's also off a popular road, and [Brad] told me he'd let me host the donor drive for free," he said. "He's my dentist and my mom works here, too."

The process of becoming a donor is easy. After having a cheek swab done, potential donors merely have to fill out a donor consent form, which will place them in the national bone marrow donor registry. Testing is then done to determine a genetic match between cancer patients and their potential donor. Patients see better results the closer a donor's genetics match his or her own.

If an individual is chosen as a blood donor, he or she will be called to Carter BloodCare to donate blood.

"A lot of people don't know it's really easy to do this -- it's not a complicated process at all," Jonathan said. "They generally don't put a needle in your hip anymore; they normally just take blood and that's it. The process is a lot simpler than it used to be."

Following a successful blood donation, known as peripheral blood stem cell donation, doctors will obtain stem cells from the blood of the donor. Those stem cells will then be given to a cancer patient that's a genetic and blood match in order to stimulate healthy red blood cell production.

If a donor is selected to give a bone marrow donation, he or she will have liquid marrow extracted from the back of the pelvic bone. This type of donation is far less likely, however.

Read this article:
Flower Mound boy hopes to add bone marrow donors: Jonathan Provost's Eagle Scout project could help save lives

Burr, the drummer with Maiden from 1979 until 1982, has been in a wheelchair as a result of multiple sclerosis, which has been attacking his nervous system since before he was diagnosed in 2002.

MS reduces the ability of the brain and spinal cord to communicate with each other, resulting in a wide range of potentially severe symptoms. The cause is unknown and there is no cure; but in 2009 researchers made the first breakthrough in reversing symptoms through stem cell therapy.

Di'Anno tells Talking Metal Pirate Radio Burr's condition is "not very good at all." - He had a lot to say, read it here.

Classic Rock Magazine is an official news provider for antiMusic.com. Copyright Classic Rock Magazine- Excerpted here with permission.

antiMUSIC News featured on RockNews.info and Yahoo News

...end

Read the rest here:
Di'Anno Wants Former Iron Maiden Bandmate To Undergo Stem Cell Therapy Recap

For Jonathan Provost, choosing his Eagle Scout project was an easy choice. Jonathan's cousin, Matthew Zieman, passed away from Acute Lymphatic Leukemia in February at the age of 24. Because of this, Jonathan's Eagle Scout project is a bone marrow donor registry drive.

"Matt was at his apartment last year and noticed a few bumps on the back of his neck," Jonathan said. "He just ignored them for a few weeks and then he told one of his friends, and she said to get it checked out. So he went by the hospital, they did a few tests, and they found out it was leukemia."

Jonathan hopes the drive will find a number of donors who can help current cancer patients, due to the difficulty of finding donor matches. Immediate family members are generally the first place doctors look for bone marrow donors; Matthew's only sibling wasn't a match, however, which made finding a donor more difficult.

The drive will be held from noon to 4 p.m. on Saturday, June 9, at Brad Duren Dentistry, located at 4030 Justin Road, Suite 102, in Flower Mound. The office is past the Chinn Chapel Soccer Complex and across from the Crossroads Bible Church. Jonathan chose the office partly because of its location and partly because of a familiarity.

"It's also off a popular road, and [Brad] told me he'd let me host the donor drive for free," he said. "He's my dentist and my mom works here, too."

The process of becoming a donor is easy. After having a cheek swab done, potential donors merely have to fill out a donor consent form, which will place them in the national bone marrow donor registry. Testing is then done to determine a genetic match between cancer patients and their potential donor. Patients see better results the closer a donor's genetics match his or her own.

If an individual is chosen as a blood donor, he or she will be called to Carter BloodCare to donate blood.

"A lot of people don't know it's really easy to do this -- it's not a complicated process at all," Jonathan said. "They generally don't put a needle in your hip anymore; they normally just take blood and that's it. The process is a lot simpler than it used to be."

Following a successful blood donation, known as peripheral blood stem cell donation, doctors will obtain stem cells from the blood of the donor. Those stem cells will then be given to a cancer patient that's a genetic and blood match in order to stimulate healthy red blood cell production.

If a donor is selected to give a bone marrow donation, he or she will have liquid marrow extracted from the back of the pelvic bone. This type of donation is far less likely, however.

Follow this link:
Flower Mound boy hopes to add bone marrow donors: Jonathan Provost's Eagle Scout project could help save lives

I was browsing the Harappa results, and two new things jumped out at me. Zack now has enough St. Thomas Christian samples from Kerala that I think we need to accept as the likely model that this community does not derive from the Brahmins of Kerala, as some of them claim. Their genetic profile is rather like many non-Brahmin South Indians, except the Nair, who have a peculiar attested history with the Brahmins of their region.

But thats not the really interesting finding. Below is a table I constructed from Zacks data.

I was curious about the distribution of the Northeast European component in South Asia. This element is almost entirely lacking in non-Brahmin South Indians (except for the Nair), but, it is present in non-Brahmin Indo-European speaking Indians, including Biharis and Bengalis. And interestingly, it is present in the same rough fraction in North Indian and South Indian Brahmins regardless of locale, ~5 percent in the former case, and ~10-15 percent in the latter. I initially divided them into two language classes, but noticed that the Maharashtra samples were more like the South Indians.

Then I remembered something random: there is a tradition dividing Indians Brahmin communities in two, on a north-south split. The above partition does not perfectly reflect the oral history and custom, but it is very close. The Brahmins of South India are a particularly homogeneous lot. Id bet that their diversity is a function of cultural evolution and adaptation to local circumstances, not disparate origins. Rather, they derive from some initial migration from a specific North Indian Brahmin community, and then admixed somewhat with another South Indian population (explaining their profiles being closer to the Southern average than that of Northern Brahmins).

Finally, most readers will be aware that I broadly accept the outline in Reconstructing Indian History. But, I do think there were multiple waves of northwest population intrusions into South Asia. In particular, I think the demographically preponderant wave was probably West Asian, while a later group brought some Eastern European ancestry into the mix as well. I think this explains nicely the fact that North Indian Brahmins have a South Indian cline but not a Northeast European cline(compare Bengali Brahmins to Punjabi Brahmins, and youll see what I mean). One possible model is that a very rapid sweep of an Indo-European speaking population may have occurred across the North Indian plain, overlain upon a local set of populations which had an ANI-ASI cline. The Genographic Project reportedly is going to present results which suggest that the Indian caste system pre-dates the arrival of the Aryans. That would comport well with this model, where earlier groups of northwesterners established a caste-like system, which the Aryans, who later formed the core of the twice-born castes, simply suited to their own needs upon arrival. If you look at Zacks results using public data sets a very low proportion of Northeastern European, equivalent to what you see in South India, is found in a few groups:

- The Dravidian Brahui and Baloch

- Tribes and Dalits

- Austro-Asiatic populations

Visit link:
Genetics’ random truths | Gene Expression

SACRAMENTO California's stem cell agency today approved two grants to UC Davis Health System researchers for their innovative work in regenerative medicine.

Kyriacos A. Athanasiou, distinguished professor of orthopaedic surgery and professor and chair of biomedical engineering, and the Child Family Professor of Engineering at UC Davis, is investigating the use of skin-derived stem cells to heal cartilage injuries and debilitating conditions of the knee such as osteoarthritis.

W. Douglas Boyd, professor of surgery, plans to further refine a novel approach to treating cardiovascular injuries suffered during a heart attack by using stem cells and a tissue-like scaffold to repair cardiac damage.

The pair received individual grants totaling approximately $6.6 million from the California Institute for Regenerative Medicine's (CIRM) governing board.

Athanasiou's and Boyd's multi-year grants were among the proposals submitted to CIRM for its third round of Early Translational Awards, which are intended to enable clinical therapies to be developed more rapidly.

"Both of these scientists are conducting exciting research that could have far-reaching implications in health care," said Jan Nolta, director of the UC Davis Institute for Regenerative Cures and the university's stem cell program director. "Dr. Athanasiou is bioengineering new cartilage that could have the same physiological integrity as the cartilage a person is born with. Dr. Boyd is developing a treatment that uses a paper-thin patch embedded with stem cells to harness their regenerative powers to repair damaged heart muscle."

Boyd, who's a pioneering cardiothoracic surgeon, pointed out in his CIRM proposal that heart disease is the nation's number-one cause of death and disability. An estimated 16.3 million Americans over the age of 20 suffer from coronary heart disease, which in 2007 accounted for an estimated 1 in 6 deaths in the U.S. Boyd plans to use bone-marrow derived stem cells -- known as mesenchymal stem cells -- in combination with a bioengineered framework known as an extracellular matrix, to regenerate damaged heart tissue, block heart disease and restore cardiac function, something currently not possible except in cases of a complete and very invasive heart transplant.

An expert in biomedical engineering, Athanasiou is focusing on developing a cellular therapy using stem cells created from an individual's own skin -- known as autologous skin-derived stem cells -- which have shown great promise in animal models. He plans to use the new funding to conduct extensive toxicology and durability tests to determine the technique's long-term safety and efficacy. Such tests are among the many steps needed to advance toward human clinical trials.

Cartilage is the slippery tissue that covers the ends of bones in joints, allowing bones to glide over each other and absorbing the shock of movement. Cartilage defects from injuries and lifelong wear and tear can eventually degenerate into osteoarthritis. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, osteoarthritis is the most common form of arthritis and affects an estimated 27 million Americans over the age of 25.

"For anyone suffering from osteoarthritis or other debilitating cartilage conditions, Dr. Athanasiou's goal of using stem cells to regenerate new tissue could have enormous quality-of-life and economic benefits," said Nolta, who is the recipient of a prior translational grant from CIRM to develop potential therapies for Huntington's disease . "Dr. Boyd's work is equally promising because he's using a bioengineered structure to encourage cardiac tissue repair, which could have important benefits in the treatment of heart disease."

Originally posted here:
State awards stem cell grants to medical researchers

DUARTE, Calif.--(BUSINESS WIRE)--

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patients own immune response against glioma stem cells. City of Hope has been awarded more than $49.7 million in grant support from CIRM since awards were first announced in 2006.

City of Hope is a pioneer in T cell immunotherapy research, helping to develop genetically modified T cells as a treatment for cancer. This strategy, termed adoptive T cell therapy, focuses on redirecting a patients immune system to specifically target tumor cells, and has the potential to become a promising new approach for treatment of cancer.

In this research, we are genetically engineering a central memory T cell that targets proteins expressed by glioma stem cells, said Stephen J. Forman, M.D., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and director of the T Cell Immunotherapy Research Laboratory. Central memory T cells have the potential to establish a persistent, lifelong immunity to help prevent brain tumors from recurring.

The American Cancer Society estimates that more than 22,000 people in the U.S. will be diagnosed with a brain tumor this year, and 13,700 will die from the disease. Glioma is a type of brain tumor that is often difficult to treat and is prone to recurrence. Currently, less than 20 percent of patients with malignant gliomas are living five years after their diagnosis. This poor prognosis is largely due to the persistence of tumor-initiating cancer stem cells, a population of malignant cells similar to normal stem cells in that they are able to reproduce themselves indefinitely. These glioma stem cells are highly resistant to chemotherapy and radiation treatments, making them capable of re-establishing new tumors.

Researchers at City of Hope previously have identified several proteins as potential prime targets for the development of cancer immunotherapies, such as interleukin 13 receptor alpha 2, a receptor found on the surface of glioma cells, and CD19, a protein that is active in lymphoma and leukemia cells. Both investigational therapies are currently in phase I clinical trials. Forman is the principal investigator for the newly granted study which will develop a T cell that targets different proteins expressed by glioma stem cells. Christine Brown, Ph.D., associate research professor, serves as co-principal investigator, and Michael Barish, Ph.D., chair of the Department of Neurosciences, and Behnam Badie, M.D., director of the Brain Tumor Program, serve as co-investigators on the project.

Because cancer stem cells are heterogeneous, our proposed therapy will target multiple antigens to cast as wide a net as possible over this malignant stem cell population, said Brown.

While in this effort, we are targeting a neurological cancer, our approach will lead to future studies targeting other cancers, including those that metastasize to the brain, added Barish.

The CIRM grant will help us to build a targeted T cell therapy against glioma that can offer lasting protection, determine the best way to deliver the treatment, establish an efficient process to manufacture these T cells for treatment, and get approval for a human clinical trial, said Badie.

City of Hope is also a collaborative partner providing process development, stem cell-derived cell products and regulatory affairs support in two other CIRM-funded projects that received early translational research grants. Larry Couture, Ph.D., senior vice president of City of Hopes Sylvia R. & Isador A. Deutch Center for Applied Technology Development and director of the Center for Biomedicine & Genetics, is working with Stanford University and Childrens Hospital of Orange County Research Institute on their respective projects.

View original post here:
City of Hope Receives $5 Million Grant to Develop T Cell Treatment Targeting Brain Tumor Stem Cells

Photo by Rachel Denny Clow, Corpus Christi Caller-Times // Buy this photo

Rachel Denny Clow/Caller-Times Cristina Rodriguez sits with her dogs Coby (left) and Flower at her home Thursday. Rodriguez, who has non-Hodgkin lymphoma, is having a Zumba benefit on Sunday and inviting people to register to donate bone marrow. Rodriguez is a former Zumba instructor.

CORPUS CHRISTI Had Cristina Rodriguez's cancer been more aggressive, had it penetrated her bones, things might have been different.

And while she has had chemotherapy, she has lost her hair and needs a stem cell treatment, but she doesn't need a bone-marrow transplant.

And for that, she's lucky.

Hispanics needing bone marrow have a harder time finding matching donors than do other ethnicities because few Hispanics have registered to donate.

"That could've easily been me," Rodriguez said.

That's why Rodriguez, 31, is trying to raise awareness about the importance for Hispanics to give bone marrow. The former Zumba instructor is hosting a Zumba event Sunday afternoon that partly is a fundraiser for her ongoing cancer treatments and partly a campaign to encourage more people to become donors.

Among the 8 million people signed up as bone marrow donors, 800,000 or 10 percent, identify themselves as Hispanic or Latino. Though Hispanics comprise more than one-third of Texas' population, only 17 percent of registered bone marrow donors in the state are Hispanic.

Overall, Hispanics have a 72 percent chance of finding a bone marrow donor, compared with whites, who have a 93 percent chance, according to the donor program. Only blacks fare worse, with a 63 percent likelihood of finding a donor.

View post:
Former Zumba instructor with cancer encourages Hispanics to donate bone marrow

Scientists turn skin cells into healthy heart tissue

Kate Kelland (Reuters) / 26 May 2012

The researchers said there were still many years of testing and refining ahead. But the results meant they might eventually be able to reprogramme patients cells to repair their own damaged hearts.

We have shown that its possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young - the equivalent to the stage of his heart cells when he was just born, said Lior Gepstein, who led the work.

The researchers, whose study was published in the European Heart Journal on Wednesday, said clinical trials of the technique could begin within 10 years.

Heart failure is a debilitating condition in which the heart is unable to pump enough blood around the body. It has become more prevalent in recent decades as advances in medical science mean many more people survive heart attacks. At the moment, people with severe heart failure have to rely on mechanical devices or hope for a transplant.

Researchers have been studying stem cells from various sources for more than a decade, hoping to capitalise on their ability to transform into a wide variety of other kinds of cell to treat a range of health conditions.

There are two main forms of stem cells - embryonic stem cells, which are harvested from embryos, and reprogrammed human induced pluripotent stem cells (hiPSCs), often originally from skin or blood.

Gepsteins team took skin cells from two men with heart failure aged 51 and 61 and transformed them by adding three genes and then a small molecule called valproic acid to the cell nucleus.

They found that the resulting hiPSCs were able to differentiate to become heart muscle cells, or cardiomyocytes, just as effectively as hiPSCs that had been developed from healthy, young volunteers who acted as controls for the study.

See the original post:
Scientists turn skin cells into healthy heart tissue

Washington, May 25 : A new study has described how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them.

UCSF scientists, working with mice, focused on treating chronic pain that arises from nerve injury -- so-called neuropathic pain.

In their study, the scientists transplanted immature embryonic nerve cells that arise in the brain during development and used them to make up for a loss of function of specific neurons in the spinal cord that normally dampen pain signals.

A small fraction of the transplanted cells survived and matured into functioning neurons. The cells integrated into the nerve circuitry of the spinal cord, forming synapses and signaling pathways with neighbouring neurons.

As a result, pain hypersensitivity associated with nerve injury was almost completely eliminated, the researchers found, without evidence of movement disturbances that are common side effects of the currently favoured drug treatment.

'Now we are working toward the possibility of potential treatments that might eliminate the source of neuropathic pain, and that may be much more effective than drugs that aim only to treat symptomatically the pain that results from chronic, painful conditions,' said the senior author of the study, Allan Basbaum, PhD, chair of the Department of Anatomy at UCSF.

Those who suffer from chronic pain often get little relief, even from powerful narcotic painkillers, according to Basbaum. Gabapentin, an anticonvulsant first used to treat epilepsy, now is regarded as the most effective treatment for neuropathic pain. However, it is effective for only roughly 30 percent of patients, and even in those people it only provides about 30 percent relief of the pain, he said.

The explanation for neuropathic pain, research showed, is that following injury neurons may be lost, or central nervous system circuitry may change, in ways that are maladaptive, compromising signals that normally help dampen pain. These changes contribute to a state of hyper-excitability, enhancing the transmission of pain messages to the brain and causing normally innocuous stimuli to become painful.

The inhibitory neurons that are damaged in the spinal cord to cause pain hypersensitivity release a molecule that normally transmits inhibitory signals ' the neurotransmitter GABA. A loss of GABA inhibition also is implicated in epilepsy and may play a role in Parkinson's disease. Gabapentin does not mimic GABA, but it helps to compensate for the loss of inhibition that GABA normally would provide.

Basbaum's UCSF colleagues, including study co-authors Arturo Alvarez-Buylla, PhD, and Arnold Kriegstein, MD, PhD, along with Scott Baraban, PhD, had already been experimenting with transplanting immature neurons that make GABA, using the transplanted neurons to bolster inhibitory signals in mouse models to prevent epileptic seizures and to combat a Parkinson's-like disease.

Continued here:
Cell therapy may ease chronic pain